Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study

BMC Women's Health

Research Article

Jamie C Barner¹  Christopher R Frei²  Kelly R Daniels³  John J Carson⁴  Andres D Ruiz⁵ 

[1] College of Pharmacy, The University of Texas, University Station A1900, 78712, Austin, TX, USA;College of Pharmacy, The University of Texas, University Station A1900, 78712, Austin, TX, USA;Pharmacotherapy Education and Research Center, The University of Texas Health Science Center, 7703 Floyd Curl Dr., MSC-6220, 78229, San Antonio, TX, USA;College of Pharmacy, The University of Texas, University Station A1900, 78712, Austin, TX, USA;Pharmacotherapy Education and Research Center, The University of Texas Health Science Center, 7703 Floyd Curl Dr., MSC-6220, 78229, San Antonio, TX, USA;Oakdell Pharmacy Inc., 7220 Louis Pasteur Dr., Suite 176, 78229, San Antonio, TX, USA;Oakdell Pharmacy Inc., 7220 Louis Pasteur Dr., Suite 176, 78229, San Antonio, TX, USA;Pharmacotherapy Education and Research Center, The University of Texas Health Science Center, 7703 Floyd Curl Dr., MSC-6220, 78229, San Antonio, TX, USA;Oakdell Pharmacy Inc., 7220 Louis Pasteur Dr., Suite 176, 78229, San Antonio, TX, USA;

关键词: Community Pharmacy;    Menopausal Symptom;    Night Sweat;    Estriol;    Mood Symptom;   

DOI  :  10.1186/1472-6874-11-27

 received in 2010-11-29, accepted in 2011-06-08,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundBioidentical Hormone Replacement Therapy (BHRT) is believed it to be a safer and equally effective alternative to Conventional Hormone Therapy for the relief of menopausal symptoms; however, data are needed to support these claims. The objective of this study is to evaluate the effectiveness of compounded BHRT provided in six community pharmacies.MethodsThis was an observational cohort study of women between the ages of 18-89 who received a compounded BHRT product from January 1, 2003 to April 30, 2010 in six community pharmacies. Data included patient demographics, comorbidities, therapeutic outcomes, and hormone therapies. Women self-rated menopausal symptoms as absent, mild, moderate, or severe. Descriptive statistics were used to characterize the patient population, BHRT use, and adverse events. Patient symptom severity was compared at baseline and 3 to 6 months follow-up using the Wilcoxon signed-rank test.ResultsWomen (n = 296) receiving BHRT at Oakdell Pharmacy had a mean (standard deviation) age of 52 (9) years. The most common BHRT dosage forms utilized were topical (71%) and oral (43%). Compounded BHRT regimens were generally initiated at low doses regardless of route. Women experienced a 25% decrease in emotional lability (p < 0.01), a 25% decrease in irritability (p < 0.01), and a 22% reduction in anxiety (p = 0.01) within 3 to 6 months. These women also experienced a 14% reduction in night sweats (p = 0.09) and a 6% reduction in hot flashes (p = 0.50).ConclusionsThis study demonstrates that compounded BHRT improves mood symptoms. Larger studies are needed to examine the impact on vasomotor symptoms, myocardial infarction and breast cancer.

【 授权许可】

Unknown   
© Ruiz et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.